Gts Securities LLC Ardelyx, Inc. Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$5.28 - $7.57 $184,272 - $264,193	-34,900 Reduced 52.25%	31,900 $219,000
Q2 2024 Aug 14, 2024	SELL	$5.89 - $9.31 $637,298 - $1.01 Million	-108,200 Reduced 61.83%	66,800 $494,000
Q1 2024 May 15, 2024	BUY	$6.05 - $9.74 $807,070 - $1.3 Million	133,400 Added 320.67%	175,000 $1.28 Million
Q4 2023 Feb 14, 2024	SELL	$3.29 - $6.64 $13,160 - $26,560	-4,000 Reduced 8.77%	41,600 $257,000
Q3 2023 Nov 15, 2023	BUY	$3.3 - $4.83 $150,480 - $220,248	45,600 New	45,600 $186,000

220

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $707M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.